Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16491630 | 0.95 | HDAC6 (0.35) | SMN1; SMN2NPC1RAB9ATP53HDAC3 | |
| SCHEMBL900949 | 0.93 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1RAB9ATP53HDAC3 | |
| SCHEMBL15493502 | 0.91 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1RAB9ATP53HDAC3 | |
| SCHEMBL30031578 | 0.89 | ALDH1A1 (0.33) | SMN1; SMN2HDAC3HDAC6KMT2AALDH1A1 | |
| SCHEMBL15080491 | 0.89 | SMN1; SMN2 (0.35) | SMN1; SMN2NPC1RAB9ATP53HDAC3 | |
| SCHEMBL346020 | 0.89 | ALDH1A1 (0.33) | SMN1; SMN2HDAC3HDAC6KMT2AALDH1A1 | |
| SCHEMBL179849 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9ATP53HDAC3 | |
| SCHEMBL7572269 | 0.86 | HTR1A (0.36) | SMN1; SMN2NPC1RAB9ATP53HDAC3 | |
| SCHEMBL182506 | 0.84 | — | — | |
| SCHEMBL17161322 | 0.84 | RGS12 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| WO-2015017316-A2 | METHODS AND COMPOSITIONS FOR MODIFYING MUCOUS MEMBRANES | ABBOTT NICHOLAS L (US) | 2015-02-05 | — | — | WO | claimed |
| US-20100003701-A1 | COVALENT MODIFICATION AND CONJUGATION OF LUCIFERASE | CARDIOGENICS INC. (CA) | 2010-01-07 | — | — | US | claimed |
| US-20070254311-A1 | Covalent modification and conjugation of luciferase | CARDIOGENICS INC. (CA) | 2007-11-01 | — | — | US | claimed |
| EP-0942996-B1 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | DIATIDE INC (US) | 2007-01-03 | — | — | EP | claimed |
| US-20060127310-A1 | Amplification of biotin-mediated targeting | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. | 2006-06-15 | — | — | US | claimed |
| EP-0832201-B1 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | UNIV ARIZONA (US) | 2005-10-05 | — | — | EP | claimed |
| EP-1206252-A4 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING POLYMERS | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2005-02-16 | — | — | EP | claimed |
| US-20030211127-A1 | Controlled dissolution crosslinked prote in crystals | ALTUS PHARMACEUTICALS INC. | 2003-11-13 | — | — | US | claimed |
| US-20020137156-A1 | CONTROLLED DISSOLUTION CROSSLINKED PROTEIN CRYSTALS | ALTUS PHARMACEUTICALS INC. | 2002-09-26 | — | — | US | claimed |
| US-6093541-A | WITH METAL PRESENTATION SURFACE HAVING IMMOBILIZED COMPLEX OF TETHERING MOLECULE AND DIGESTION MOLECULE; FOR RAPID AND EFFICIENT ANALYSIS OF BIOMOLECULES USING MATRIX-ASSISTED LASER DESORPTION/IONIZATION TECHNIQUE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 2000-07-25 | — | — | US | claimed |
| EP-0973878-A1 | CONTROLLED DISSOLUTION CROSS-LINKED PROTEIN CRYSTALS | Altus Biologics Inc. (US) | 2000-01-26 | — | — | EP | claimed |
| US-6004770-A | MASS SPECTROMETRY SAMPLE PRESENTATION APPARATUSES DERIVATIZED WITH COMPLEXES INCLUDING AT LEAST ONE MOLECULE WHICH MODIFIES A BIOMOLECULE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 1999-12-21 | — | — | US | claimed |
| US-5951981-A | A CROSSLINKED THROMBOLYTIC PROTEINASE, E.G. FIBROLASE FROM AGKISTRODOON CONTORTRIX CONFORTRIX VENOM, AND A BINDING PEPTIDE THAT BINDS AT THE SITE OF BLOOD CLOTS AND THROMBI; SIDE EFFECTS REDUCTION | DIATIDE, INC. (US) | 1999-09-14 | — | — | US | claimed |
| WO-1998046732-A1 | CONTROLLED DISSOLUTION CROSS-LINKED PROTEIN CRYSTALS | ALTUS BIOLOGICS INC. (US) | 1998-10-22 | — | — | WO | claimed |
| WO-1997043645-A1 | ANTIBODIES DIRECTED AGAINST DITHIOCARBAMATES | MEDINOX, INC. (US) | 1997-11-20 | — | — | WO | claimed |
| EP-0701448-A4 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-01-02 | — | — | EP | claimed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | claimed |
| US-5449720-A | Amplification of the VB12 uptake system using polymers | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1995-09-12 | — | — | US | claimed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | SMN1; SMN2 1489/4885NPC1 4476/4885RAB9A 4326/4885 |
| US-20060127310-A1 | Amplification of biotin-mediated targeting | BTD, HLCS, SLC1A5 | SMN1; SMN2 4527/4885NPC1 357/4885RAB9A 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.